Business Context and Reporting Period
Company: Novo Nordisk A/S
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: November 6, 2025
Context: Announcement of a strategic agreement with the U.S. Administration regarding pricing, access, and coverage for semaglutide medicines (Wegovy® and Ozempic®).
Key Financial Metrics and Material Changes
This filing is a qualitative announcement and does not contain specific financial statements, revenue figures, profit margins, or cash flow data for the current period.
- Material Change: Agreement to lower prices for semaglutide medicines in U.S. Medicare Part D, Medicaid, and direct-to-patient cash channels starting in 2026.
- Impact on Growth: Management expects a direct, negative low single-digit impact on global sales growth in 2026 due to the pricing agreement.
- Regulatory Benefit: Novo Nordisk is expected to receive a three-year tariff exemption.
- Access Expansion: Obesity medicines will be covered in U.S. Medicare Part D via a pilot program starting in 2026, designed to cover a majority of beneficiaries.
Guidance, Outlook, and Management Commentary
Management Commentary: CEO Mike Doustdar stated the agreement secures affordable access and expands obesity medication access in Medicare, allowing patients to access authentic Wegovy®.
Outlook and Guidance:
- 2026 Sales Growth: Estimated negative low single-digit impact on global sales growth.
- Implementation: Expected to begin in 2026.
- Future Reporting: The full financial outlook for 2026 will be provided in connection with the full-year 2025 results announcement on February 4, 2026.
Risks and Contingencies: The filing notes that details of the agreement are to be finalized. Forward-looking statements are subject to risks outlined in the financial report for the first nine months of 2025 (Company Announcement No 31/2025).
Key Facts for Investor Verification
- Verify the specific magnitude of the "negative low single-digit" sales growth impact once the 2026 outlook is released in February 2026.
- Monitor the finalization of the agreement details with the U.S. Administration to confirm the scope of the Medicare Part D pilot program.
- Confirm the terms and duration of the three-year tariff exemption.
- Review the full-year 2025 results (scheduled for February 4, 2026) for updated financial guidance reflecting this agreement.